Psoriasis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• IL-17 12
• IL-23 6
• STAT3 0
• TNF 5
• JAK 1
• GLP-1 5
• TYK2 1
• PI3K 0
• NLRP3 0
• IL-6 0
• IL-1 0
• AKT 0
• MAPK 0
• PDE4 1
• NRF2 0
• PD-1 0
• PPAR 0
• STING 0
• mTOR 0
• TLR4 0
• AMPK 0
• ERK 0
• VEGF 0
• GIP 1
• MMP-9 0
• PD-L1 0
• COX-2 0
• HIF-1 0
• IL-4 0
• SIRT1 0
• TP53 0
• APOE 0
• CGRP 0
• IL-13 0
• KEAP1 0
• LAG-3 0
• PCSK9 0
• PKM2 0
• SGLT2 0
• TSLP 0
• AR 0
• BCL-2 0
• BDNF 0
• BRD4 0
• CD123 0
• CD19 0
• CD40 0
• CSF1R 0
• CTLA-4 0
• CTNNB1 0
• CXCR4 0
• EGFR 0
• EZH2 0
• FTO 0
• G6PD 0
• GPRC5D 0
• HDAC 0
• HMGB1 0
• HSP90 0
• IDH 0

3 of 3+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · F32

  Understanding the role of innate lymphoid cells within psoriasis relapse

  Ohio State University· Columbus, United States· US$84,580 awarded in fiscal year 2026· until Sept 2027

• NIH NIAMS · R56

  Leading Edge Propogation Mechanism of Human Keloid Scars

  University of California Riverside· Riverside, United States· US$712,693 awarded in fiscal year 2026· until Aug 2027

• NIH NINDS · RF1

  The peripheral mechanisms underlying mechanical itch

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$1,397,313 awarded in fiscal year 2026· until Aug 2029

• NIH NHGRI · R44

  Cell Locker kit: A whole blood fixative chemistry kit for preserving single cell gene expression at room temperature to enable geographical reach of patient-centric at-home immune monitoring

  Imyoo Inc· Mountain View, United States· US$794,486 awarded in fiscal year 2026· until Aug 2028

• NIH NIAMS · R01

  Regulation of epidermal differentiation via delamination and oriented cell divisions

  Univ of North Carolina Chapel Hill· Chapel Hill, United States· US$469,412 awarded in fiscal year 2026· until Jun 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Synergistic Nano-Therapeutic Approach for Psoriasis: Targeting TNF-α and IL-17 Pathways via Transdermal Delivery (SKINNOVATE)

  Academisch Ziekenhuis Groningen· Groningen, Netherlands· EU contribution €232,916· until Oct 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Unmasking Non-Genetic Determinants Instructing Tumor Initiation (IGNITE)

  Fundacio Institut de Recerca Biomedica (Irb Barcelona)· Barcelona, Spain· EU contribution €1,995,000· until Sept 2030

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Positive allosteric modulators of the PD-1•PD-L1 interaction as a new mode of therapeutic intervention for autoimmune diseases: preclinical proof of concept in humanized mice (PAMinMICE)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €150,000· until Feb 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Dissolving microneedle array patch-based psoriatic immunotherapy using nanoparticles (MAPiT)

  Stockholms Universitet· Stockholm, Sweden· EU contribution €222,728· until Feb 2027

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification (Lab-In-Skin)

  Universiteit Twente· Enschede, Netherlands· EU contribution €150,000· until Dec 2026

  The disease is named only in the funder's project summary, not in the title.

10 of 197 running projects, newest first. Listed amounts together: US$117.2m + €31.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 28
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 4
• Gene Expression Profiling 66
• Sequence Analysis, RNA 6
• Exome Sequencing 5
• Proteomics 24
• Metabolomics 13
• Flow Cytometry 11
• Immunohistochemistry 24
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 23
• Machine Learning 27
• Deep Learning 4
• Cohort Studies 63
• Genome-Wide Association Study 38

• Immunohistochemical investigation of transferrin receptor 2 (TFR2) immunoreactivity in patients with psoriasis vulgaris.

  Cutan Ocul Toxicol, May 2026

• Immunohistochemical Evaluation of GATA3 Expression in Patch-Stage Mycosis Fungoides (MF) Compared With Benign Inflammatory Dermatoses (BID).

  J Cutan Pathol, May 2026

• Immunohistochemistry Revealed Distinct IL-36γ Localization Among Different Skin Diseases.

  J Dermatol, May 2026

• The role of angiogenesis in psoriasis: An analysis of vascular endothelial growth factor ( VEGF ) and CD31 expression.

  Indian J Pathol Microbiol, Apr 2026

• IL-17, IL-23, and IL-36α Expression in Palmoplantar Psoriasis, Palmoplantar Eczema, and Plaque Psoriasis: Implications on Diagnosis and Treatment Selection.

  J Cutan Pathol, Mar 2026

• Spatial transcriptomic profiling reveals body site-specific inflammatory differences in psoriasis lesions.

  Front Immunol, Mar 2026

• Effect of Platelet-Rich Plasma Versus Platelet Lysate on Imiquimod-Induced Psoriasis-Like Skin Inflammation in Adult Male Albino Rat Model: A Histological, Immunohistochemical, and Ultrastructural Study.

  Microsc Microanal, Mar 2026

• Three‑dimensional immune cartography uncovers subclinical remodeling in psoriasis.

  Sci Rep, Feb 2026

• Harnessing Digital Pathology Tools to Distinguish Hand Eczema From Palmar Psoriasis: A Quantitative Approach.

  J Cutan Pathol, Feb 2026

• Localized palmar mycosis fungoides: A case report.

  Medicine (Baltimore), Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.